kidins220b Antibody

What is KIDINS220 and what are its main cellular functions?

KIDINS220, also known as ARMS (Ankyrin Repeat-Rich Membrane Spanning protein), is a highly conserved multidomain transmembrane protein containing four putative transmembrane domains and several ankyrin repeats. It functions primarily as:

• A substrate for protein kinase D

• A downstream target for both tropomyosin receptor kinase (Trk) and ephrin (Eph) receptors

• A scaffolding protein mediating signal transduction in neural tissues

• A regulator of B cell receptor (BCR) signaling

• A modulator of cytoskeletal network stability

KIDINS220 is prominently expressed in regions rich in neurotrophin receptors, particularly in the brain and neuroendocrine cells, where it concentrates at neurite tips. It's also found in peripheral blood immature dendritic cells and PC12 cells .

Which applications are KIDINS220 antibodies typically validated for?

Commercial KIDINS220 antibodies have been validated for multiple applications as shown in the following table:

Selection of the appropriate antibody depends on your specific application, target species, and experimental design .

What species reactivity do KIDINS220 antibodies typically demonstrate?

KIDINS220 antibodies vary in their species reactivity profiles:

• Human-specific: Several commercial antibodies are validated specifically for human samples

• Multi-species: Some antibodies recognize both human and rat KIDINS220 (e.g., CSB-PA928650)

• Species-specific monoclonal antibodies: Some laboratories have developed antibodies that specifically recognize either human or mouse KIDINS220-C33 isoform

• Predicted cross-reactivity: Many rabbit polyclonal antibodies show predicted reactivity with mouse (92%) and rat (94%) based on sequence homology

When selecting an antibody, verify the validated species reactivity in the product documentation and consider testing cross-reactivity in your specific experimental system .

How should KIDINS220 antibodies be stored and handled to maintain optimal activity?

Proper storage and handling are crucial for maintaining antibody functionality:

• Storage temperature: Most KIDINS220 antibodies require storage at -20°C or -80°C

• Storage buffer considerations: Common formulations include:

  • PBS with 0.05% NaN3 and 40% glycerol (CSB-PA928650)

  • PBS only (66748-1-PBS)

• Avoid repeated freeze-thaw cycles: This can lead to protein denaturation and reduced antibody activity

• Working dilutions: Prepare fresh working dilutions on the day of experiment

  • Typical working dilutions: 1:500-1:2000 for Western blot applications

  • 1:500 for immunohistochemistry applications

Always refer to the manufacturer's specific recommendations for your particular antibody preparation .

What are the optimal dilutions and controls for Western blot applications with KIDINS220 antibodies?

For successful Western blot detection of KIDINS220:

• Loading controls: Include appropriate housekeeping proteins (β-actin, GAPDH)

• Expected molecular weight: KIDINS220 is typically observed at approximately 200 kDa

  • Note that KIDINS220 exists in multiple isoforms with molecular weights of approximately 194 kDa, 185 kDa, 115 kDa, and 60 kDa

• Recommended dilutions:

  • 1:1000 for ab97345

  • 1:500-1:2000 for most other commercial antibodies

• Negative controls: Consider using KIDINS220 knockout cells or tissues where available

• Reducing conditions: 5% SDS-PAGE is suitable for separation

When analyzing Western blot results, be aware that post-translational modifications may affect protein migration and band patterns .

How can I distinguish between different KIDINS220 isoforms in my experiments?

KIDINS220 exists in multiple isoforms that can be distinguished through careful experimental design:

• Isoform-specific antibodies: Use antibodies targeting unique regions

  • Kidins220-C32 antibody recognizes both human and mouse isoforms

  • Kidins220-C33 monoclonal antibodies can be species-specific (human-only or mouse-only)

  • Kid-Nt antibody recognizes the N-terminal region

• RT-PCR approach: Design primers spanning specific exon junctions to detect different splice variants

• Molecular weight differentiation: KIDINS220 isoforms display distinct molecular weights:

  • 194 kDa

  • 185 kDa

  • 115 kDa

  • 60 kDa

• Subcellular localization studies: Different isoforms may show distinct localization patterns that can be detected via immunofluorescence

When studying calpain-derived fragments (such as Nt-7/8), be aware that antibody specificity may be limited .

What are the key signaling pathways affected by KIDINS220, and how can antibodies help elucidate these mechanisms?

KIDINS220 influences multiple signaling pathways that can be investigated using antibodies against both KIDINS220 and downstream effectors:

• MAPK signaling pathway:

  • KIDINS220 promotes prolonged MAP-kinase signaling through Rap1-dependent mechanisms

  • Antibodies against phosphorylated ERK can detect reduced signaling in KIDINS220-deficient cells

  • Experimental approach: Compare phospho-ERK levels in control vs. KIDINS220 knockout cells

• AKT/GSK3 pathway in neural stem cells:

  • KIDINS220 activates AKT in response to EGF, restraining GSK3 activity

  • Use phospho-AKT and phospho-GSK3 antibodies to monitor pathway activation

  • Data shows KIDINS220 loss limits EGFR responsiveness to ligands

• BCR signaling in B cells:

  • KIDINS220 couples BCR to PLCγ2, Ca²⁺, and ERK signaling

  • Experimental approach: Monitor phosphorylation of SYK, SLP65, p65, and ERK in control vs. B-cell-specific KIDINS220 knockout models

• Neurotrophin signaling:

  • KIDINS220 provides a docking site for CRKL-C3G complex

  • Serves as connection point between neurotrophin receptors and downstream effectors

Each pathway analysis should include appropriate positive and negative controls to ensure reliability of results .

How does KIDINS220 influence B cell development, and what experimental approaches can investigate this function?

KIDINS220 plays a critical role in B cell development, particularly affecting B cells bearing the λ light chain:

Experimental findings:

• B cell-specific Kidins220 knockout (B-KO) mice show:

  • Almost complete loss of λ light chain (λLC) B cells in bone marrow and periphery

  • Relatively mild effects on κ light chain (κLC) compartment

  • Sixfold reduction in λLC-positive B cells

Mechanisms identified:

• KIDINS220 supports B cell precursor survival

• Optimizes pre-BCR and BCR signaling

• Extends the time window for Igl locus opening, recombination, and transcription

• Enhances reactive oxygen species (ROS) production in developing B cells

Experimental approaches to investigate these functions:

• Flow cytometry analysis of B cell populations in control vs. B-KO mice

• Retroviral transduction to overexpress BTK in pro/pre-B cell cultures

• BCL2 overexpression to assess survival effects

• DCFDA labeling to measure cellular ROS production

• MitoTracker Red to examine mitochondrial mass and activity

• Receptor editing studies using κ-macroself transgenic mice

These methodologies have revealed that KIDINS220's dual function in regulating BCR signaling and supporting B cell survival is essential for normal B cell development .

How can researchers validate the specificity of KIDINS220 antibodies in their experimental systems?

Rigorous validation of KIDINS220 antibodies is essential for reliable results:

• Genetic validation approaches:

  • Test antibody in KIDINS220 knockout models (complete or conditional)

  • Use CRISPR/Cas9-mediated KIDINS220 knockdown cells

  • Compare B cell-specific Kidins220 knockout (B-KO) with control tissues

• Immunological validation methods:

  • Peptide competition assays using the immunogenic peptide

  • Compare staining patterns across multiple antibodies targeting different KIDINS220 epitopes

  • Verify molecular weight in Western blot (expected ~200 kDa)

• Technical controls:

  • Include isotype control antibodies in immunostaining

  • Use secondary-only controls to assess background

  • Verify subcellular localization patterns match known KIDINS220 distribution

• Cross-reactivity assessment:

  • Test the antibody on tissues from different species if cross-reactivity is claimed

  • Compare staining patterns in tissues with known high versus low KIDINS220 expression

For antibodies used in immunohistochemistry, verify that staining patterns match expected cellular distribution (e.g., cytoplasmic positivity in glandular cells for NBP1-88995) .

What role does KIDINS220 play in neurogenesis, and how can antibodies help investigate this function?

KIDINS220 serves as a key regulator of neural stem cell (NSC) survival and function:

Key findings from neurogenesis research:

• KIDINS220 functions as an intrinsic regulator of NSCs in adult neurogenic niches

• Decreased KIDINS220 expression causes:

  • Severe neurogenic deficits

  • Increased neuroblast death

  • Loss of newborn neurons in the subgranular zone (SGZ)

  • Impaired hippocampal-based spatial memory

Molecular mechanisms:

• KIDINS220-dependent activation of AKT in response to EGF restrains GSK3 activity

• KIDINS220 loss limits EGFR capacity to respond to ligands

• KIDINS220 sets the molecular threshold for NSC survival

Experimental approaches using antibodies:

• Immunohistochemistry to assess KIDINS220 expression in neurogenic niches

• Western blot analysis to compare KIDINS220 levels in GfapΔ/Δ Kidins220 and wild-type mice

• Immunofluorescence to examine co-localization with neural stem cell markers

• Antibodies against downstream signaling molecules (pAKT, pGSK3) to monitor pathway activation

These findings identify KIDINS220 as a critical player in sensing growth factor availability to sustain adult neurogenesis, making it a potential target for therapeutic strategies targeting neurodegenerative disorders .

How are KIDINS220 isoforms differentially regulated in Huntington's disease, and what methodological considerations are important when studying this?

Research has identified differential regulation of KIDINS220 isoforms in Huntington's disease:

Methodological considerations:

• Antibody selection is critical:

  • Rabbit polyclonal Kidins220-C32 antibody recognizes both human and mouse variants

  • Different rabbit monoclonal antibodies for Kidins220-C33 are species-specific

  • Kid-Nt antibody recognizes the N-terminal region but may not reliably detect certain fragments

• Western blot analysis requirements:

  • Use neuronal-specific markers (NSE, NeuN) as controls

  • Include β-actin and spectrin as loading controls

  • Analyze Huntingtin (Htt) protein levels in parallel

• Immunohistochemistry considerations:

  • Use appropriate fluorescent secondary antibodies (AlexaFluor 488, 546, 647)

  • Apply appropriate dilutions (1:500 for immunohistochemistry)

  • Include controls for antibody specificity

• Fragment analysis:

  • Be aware that Nt-7/8 calpain-derived fragments cannot be unequivocally detected by Kid-Nt antibody

When designing experiments to investigate KIDINS220 in Huntington's disease, researchers should carefully select antibodies that can differentiate between relevant isoforms and fragments, and include appropriate controls to ensure reliable detection and quantification .

What experimental approaches can be used to study the interaction between KIDINS220 and the B cell antigen receptor (BCR)?

The interaction between KIDINS220 and BCR can be investigated through several sophisticated approaches:

• Co-immunoprecipitation studies:

  • KIDINS220 has been shown to bind IgD-, IgM-, and IgG2a-BCR

  • The interaction increases upon BCR stimulation in a Src kinase-independent manner

  • Negative controls should include non-BCR membrane proteins (e.g., MHC class I)

• Mass spectrometry:

  • This approach initially identified KIDINS220 as a novel BCR interaction partner

  • Can be used to map interaction domains and identify additional components

• Functional studies in knockout models:

  • B cell-specific Kidins220 knockout (B-KO) mice show reduced BCR signaling

  • Analysis should include assessment of PLCγ2, Ca²⁺, and ERK activation

• Cell line models:

  • J558L cells (lacking BCR expression) serve as negative controls

  • Primary splenic B cells from B1-8/IEKT mice provide physiologically relevant models

• Signaling pathway analysis:

  • Monitor phosphorylation of downstream molecules (SYK, SLP65, ERK)

  • Measure reactive oxygen species (ROS) as second messengers

  • Assess impact on mitochondrial function using MitoTracker Red

These approaches have revealed that KIDINS220 plays a crucial role in coupling the BCR to downstream signaling pathways, particularly affecting B cells bearing the λ light chain .

What are the most common technical challenges when using KIDINS220 antibodies, and how can they be addressed?

Researchers working with KIDINS220 antibodies may encounter several technical challenges:

• Detecting high molecular weight protein:

  • Challenge: KIDINS220 (~200 kDa) can be difficult to transfer efficiently in Western blots

  • Solution: Use extended transfer times or specialized high-molecular-weight transfer protocols

  • Consider using gradient gels (4-15%) for better separation

• Isoform specificity:

  • Challenge: KIDINS220 exists in multiple isoforms that may cross-react

  • Solution: Carefully select antibodies targeting specific regions

  • Validate results using multiple antibodies targeting different epitopes

• Background signal in immunostaining:

  • Challenge: Nonspecific binding can obscure true signal

  • Solution: Optimize blocking conditions (consider using 5% BSA instead of milk)

  • Include appropriate controls (isotype controls, secondary-only controls)

• Storage stability:

  • Challenge: Antibody degradation during storage

  • Solution: Aliquot antibodies upon receipt to avoid freeze-thaw cycles

  • Store at recommended temperatures (-20°C or -80°C)

• Species cross-reactivity limitations:

  • Challenge: Some antibodies show limited cross-species reactivity

  • Solution: Verify species reactivity in product documentation

  • Test reactivity empirically in your system before proceeding with extensive experiments

• Detection of proteolytic fragments:

  • Challenge: Calpain-mediated cleavage generates fragments that may not be detected by all antibodies

  • Solution: Use antibodies targeting different epitopes to capture the full range of fragments

Careful optimization of protocols for your specific experimental system can help overcome these challenges .

How can researchers optimize immunohistochemistry protocols for KIDINS220 detection in different tissue types?

Optimizing immunohistochemistry for KIDINS220 detection requires attention to several parameters:

• Tissue fixation and processing:

  • Formalin-fixed paraffin-embedded (FFPE) tissues: Optimize antigen retrieval methods

  • Fresh frozen tissues: May provide better epitope preservation but require different handling

  • Consider fixation time (overfixation can mask epitopes)

• Antibody selection and dilution:

  • Validated antibodies: NBP1-88995 and ab97345 have been validated for IHC-P

  • Starting dilutions: 1:500 is typically recommended, but optimization may be necessary

  • Consider testing a dilution series (1:200, 1:500, 1:1000) to determine optimal signal-to-noise ratio

• Antigen retrieval methods:

  • Heat-induced epitope retrieval: Test different pH buffers (citrate pH 6.0 vs. EDTA pH 9.0)

  • Enzymatic retrieval may be necessary for some tissue types

  • Optimization of retrieval time and temperature is crucial

• Detection systems:

  • Polymer-based detection systems often provide better sensitivity than ABC methods

  • Fluorescence detection allows for colocalization studies with other markers

  • Chromogenic detection may be preferable for morphological studies

• Tissue-specific considerations:

  • Neural tissues: KIDINS220 shows strong expression in neurons, particularly at neurite tips

  • B cells: Expression may be more diffuse and require signal amplification

  • Glandular tissues: Strong cytoplasmic positivity has been observed in glandular cells

• Controls:

  • Positive tissue controls (brain tissue is recommended)

  • Negative controls (omission of primary antibody)

  • Comparison with known expression patterns

Empirical optimization using these parameters will help establish reliable IHC protocols for KIDINS220 detection across different tissue types .

What emerging research areas involve KIDINS220, and how might antibody-based techniques contribute to these investigations?

Several promising research areas involving KIDINS220 are emerging:

• Neurodegenerative diseases:

  • KIDINS220's role in neuronal survival makes it relevant to conditions like Huntington's disease

  • Antibodies can help track isoform-specific changes in disease progression

  • Potential approach: Compare KIDINS220 expression and localization in patient samples versus controls

• Immune system dysregulation:

  • KIDINS220's impact on B cell development suggests relevance to immune disorders

  • Antibodies can help assess KIDINS220 levels in patient-derived B cells

  • Research potential: Investigating KIDINS220 in autoimmune conditions where B cell function is altered

• Adult neurogenesis and neural repair:

  • KIDINS220 regulates neural stem cell survival and EGF responsiveness

  • Antibodies enable tracking of KIDINS220 expression in neurogenic niches

  • Application: Monitoring KIDINS220 levels during neural regeneration after injury

• Cancer biology:

  • KIDINS220 modulates stress-induced apoptosis in melanoma cells via MEK/ERK signaling

  • Antibodies can help assess KIDINS220 expression across tumor types

  • Research direction: Exploring KIDINS220 as a potential biomarker or therapeutic target

• Developmental biology:

  • The evolutionary conservation of KIDINS220 suggests critical developmental roles

  • Antibodies enable tracking of expression patterns during embryogenesis

  • Application: Investigating KIDINS220 in models of developmental disorders

These emerging areas will benefit from continued development and validation of high-quality antibodies against KIDINS220 and its various isoforms .

How can researchers design experiments to investigate the relationship between KIDINS220 and specific signaling pathways?

Investigating KIDINS220's relationship with signaling pathways requires thoughtful experimental design:

• For MAPK/ERK pathway interactions:

  • Compare phospho-ERK levels in control versus KIDINS220-deficient cells

  • Use phospho-specific antibodies for temporal analysis after stimulation

  • Analyze Rap1 activation as a potential mediator

  • Consider rescue experiments with constitutively active pathway components

• For B cell receptor signaling:

  • Design flow cytometry panels to assess multiple phospho-proteins simultaneously

  • Measure calcium flux in response to BCR stimulation

  • Analyze reactive oxygen species (ROS) production using DCFDA labeling

  • Test BTK overexpression as a potential rescue strategy

• For neurotrophin receptor signaling:

  • Assess BDNF-induced signaling in control vs. KIDINS220-deficient neurons

  • Analyze CRKL-C3G complex formation and Rap1 activation

  • Investigate the recruitment of RAPGEF2 to late endosomes

  • Monitor neurite outgrowth as a functional readout

• For AKT/GSK3 pathway in neural stem cells:

  • Compare phospho-AKT and phospho-GSK3 levels after EGF stimulation

  • Analyze downstream effects on cell survival and apoptosis markers

  • Consider genetic manipulation of pathway components to rescue phenotypes

  • Include time-course analyses to capture both immediate and sustained signaling

These approaches can help delineate the specific roles of KIDINS220 in various signaling contexts and potentially identify novel therapeutic targets .